HLA 1 & 2 Patient HLA Tissue Typing at Lahore PCR Lab

HLA 1 & 2 (Patient) HLA Tissue Typing at Lahore PCR Lab

Human Leukocyte Antigen (HLA) typing, commonly referred to as tissue typing, is a highly specialized molecular diagnostic procedure used to identify the unique genetic markers on the surface of an individual’s cells. These proteins, encoded by the Major Histocompatibility Complex (MHC) gene family on chromosome 6, play a pivotal role in the body’s immune system, allowing it to distinguish between self and non-self entities. At Lahore PCR Lab in Lahore, Pakistan, the HLA 1 & 2 (Patient) HLA Tissue Typing test is performed using advanced molecular diagnostic techniques, specifically Polymerase Chain Reaction (PCR), to deliver high-resolution genetic profiling essential for clinical decision-making.

The HLA system is broadly divided into two major classes: Class I (which includes HLA-A, HLA-B, and HLA-C loci) and Class II (which includes HLA-DR, HLA-DQ, and HLA-DP loci). Class I molecules are expressed on almost all nucleated cells in the body and present endogenous peptides to CD8+ cytotoxic T-lymphocytes. Class II molecules are primarily expressed on professional antigen-presenting cells, such as dendritic cells, macrophages, and B-lymphocytes, presenting exogenous peptides to CD4+ helper T-lymphocytes. Accurate identification of these alleles is fundamental in modern medicine, particularly in the fields of transplantation immunology, autoimmune disease diagnostics, and pharmacogenomics.

The clinical importance of HLA typing cannot be overstated. In solid organ transplantation (such as kidney, liver, or heart transplants) and hematopoietic stem cell transplantation (HSCT), matching the HLA profiles of the donor and the recipient is the single most critical factor in predicting graft survival, preventing hyperacute or chronic graft rejection, and minimizing the risk of life-threatening Graft-Versus-Host Disease (GVHD). Beyond transplantation, specific HLA alleles are strongly associated with various autoimmune, inflammatory, and infectious diseases, as well as severe adverse drug reactions. By utilizing state-of-the-art PCR technology, Lahore PCR Lab ensures that patients receive highly precise, reproducible, and clinically actionable HLA typing results to guide their medical journeys.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the highest accuracy and prevent sample contamination or degradation, patients undergoing HLA 1 & 2 Tissue Typing at Lahore PCR Lab should observe the following preparation guidelines:

• No Fasting Required: Fasting is not necessary for this molecular test. Patients may eat, drink, and take their routine medications normally prior to sample collection.
• Disclose Medical History: It is imperative to inform the laboratory staff if you have recently received a blood transfusion (within the last 3 months) or have undergone a bone marrow transplant, as donor DNA can temporarily or permanently interfere with the accuracy of the patient’s genetic profile.
• Immunosuppressive Medications: While routine medications do not affect DNA structure, patients should inform their healthcare provider of any immunosuppressive therapies they are undergoing, as this provides vital clinical context for the referring physician.
• Hydration: Staying well-hydrated is recommended to facilitate easier venous access during the blood draw.

During the Procedure

The collection of the biological sample for HLA typing is a quick, safe, and routine procedure performed by experienced phlebotomists at Lahore PCR Lab:

• Patient Identification and Verification: The phlebotomist will verify the patient’s identity using official identification documents and match it with the laboratory requisition form to ensure absolute traceability.
• Venipuncture Site Selection: The patient will be seated comfortably, and a suitable vein, typically in the antecubital fossa (inner elbow), will be selected.
• Aseptic Technique: The skin over the selected vein will be thoroughly cleansed with an antiseptic solution (such as 70% isopropyl alcohol) to prevent microbial contamination.
• Sample Collection: A sterile, single-use needle will be inserted into the vein to collect approximately 3 to 5 milliliters of whole blood into an EDTA (ethylenediaminetetraacetic acid) tube. EDTA is the preferred anticoagulant as it preserves cellular integrity and prevents DNA degradation.
• Post-Collection Care: The needle is gently withdrawn, and a sterile cotton swab or adhesive bandage is applied to the puncture site. Patients are advised to apply gentle pressure for a few minutes to stop any minor bleeding.
• Safety and Comfort: The entire venipuncture process takes less than five minutes. Patients may feel a mild, brief pinching sensation as the needle enters the skin. The procedure is highly safe, with minimal risks such as minor bruising or localized soreness at the injection site.

When is an HLA 1 & 2 Tissue Typing Performed?

Solid Organ Transplantation Matching

Physicians request HLA Class I and Class II typing when a patient is being evaluated for solid organ transplantation, such as a renal (kidney) transplant. The test is performed on both the prospective recipient and potential living or deceased donors. By comparing the HLA-A, HLA-B, and HLA-DR loci, transplant surgeons can assess the degree of histocompatibility. A closer HLA match significantly reduces the risk of the recipient’s immune system recognizing the donor organ as foreign, thereby preventing acute cellular rejection, antibody-mediated rejection, and long-term graft failure, while potentially reducing the required dosage of post-transplant immunosuppressive therapy.

Hematopoietic Stem Cell and Bone Marrow Transplantation

In patients diagnosed with hematological malignancies (such as leukemia, lymphoma, or multiple myeloma) or severe hematological disorders (such as aplastic anemia or thalassemia), a hematopoietic stem cell transplant (HSCT) may be the only curative option. For HSCT, high-resolution HLA typing of both Class I and Class II alleles is mandatory. Unlike solid organ transplants, stem cell transplants require an extremely close match (ideally an 8/8 or 10/10 match across HLA-A, -B, -C, -DRB1, and -DQB1) to prevent Graft-Versus-Host Disease (GVHD), a life-threatening condition where the donor’s immune cells attack the recipient’s tissues, or graft failure, where the recipient’s residual immune system rejects the donor stem cells.

Autoimmune and Inflammatory Disease Association

Certain HLA alleles are highly correlated with an increased susceptibility to specific autoimmune and chronic inflammatory disorders. For instance, the presence of the HLA-B27 allele is strongly linked to ankylosing spondylitis, reactive arthritis, and anterior uveitis. Similarly, HLA-DQ2 and HLA-DQ8 alleles are primary genetic markers for celiac disease, an autoimmune enteropathy triggered by gluten ingestion. When a patient presents with ambiguous joint pain, chronic back pain, or gastrointestinal symptoms, physicians utilize HLA typing as a diagnostic aid to rule out or support these complex autoimmune diagnoses.

Drug Hypersensitivity Screening

In the era of personalized medicine, HLA typing has become a critical tool for predicting severe, life-threatening drug hypersensitivity reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). For example, patients carrying the HLA-B*5701 allele are at an exceptionally high risk of developing a severe hypersensitivity reaction to the antiretroviral drug abacavir, used in HIV treatment. Similarly, the HLA-B*1502 allele is strongly associated with carbamazepine-induced SJS/TEN in certain populations. Screening patients for these specific HLA markers before initiating therapy prevents severe adverse drug events and ensures patient safety.

Platelet Transfusion Refractoriness Management

Patients who receive multiple platelet transfusions, such as those undergoing intensive chemotherapy, may develop antibodies against foreign HLA Class I molecules present on the donor platelets. This immune response leads to the rapid destruction of transfused platelets, a condition known as HLA-mediated platelet refractoriness, resulting in a failure to achieve the expected post-transfusion platelet count increment. In such cases, HLA typing of the patient is performed to identify their specific Class I profile, allowing blood banks to select HLA-matched or HLA-compatible platelet donors to ensure therapeutic efficacy and prevent severe bleeding complications.

What Does an HLA 1 & 2 Tissue Typing Detect?

The HLA 1 & 2 (Patient) HLA Tissue Typing test at Lahore PCR Lab is designed to detect and identify specific alleles across both Class I and Class II loci. Clinical findings and detections include:

• HLA-A Loci Alleles: Identifies specific Class I alleles (e.g., HLA-A*02, HLA-A*24) to establish baseline histocompatibility.
• HLA-B Loci Alleles: Detects Class I B alleles, critical for transplant matching and disease association.
• HLA-C Loci Alleles: Identifies Class I C alleles, which play a key role in natural killer (NK) cell interactions and transplant compatibility.
• HLA-DRB1 Loci Alleles: Detects highly polymorphic Class II DRB1 alleles, the most critical class II markers for organ and stem cell matching.
• HLA-DQB1 Loci Alleles: Identifies Class II DQB1 alleles, essential for celiac disease screening and transplant matching.
• HLA-DPB1 Loci Alleles: Evaluates Class II DPB1 alleles, providing high-resolution matching data for bone marrow transplantation.
• HLA-B*27 Allele: Detects the presence of this marker, indicating a strong genetic predisposition to ankylosing spondylitis and related spondyloarthropathies.
• HLA-B*5701 Allele: Identifies patients at risk of abacavir hypersensitivity syndrome.
• HLA-B*1502 Allele: Detects susceptibility to carbamazepine-induced Stevens-Johnson Syndrome.
• HLA-DQ2.5 and HLA-DQ8: Identifies genetic susceptibility to celiac disease; a negative result virtually rules out the condition.
• HLA-DR4 Allele: Associated with an increased risk of developing rheumatoid arthritis.
• HLA-DR3 and HLA-DR4: Associated with genetic susceptibility to Type 1 Diabetes Mellitus.
• HLA-DRB1*15:01 Allele: Associated with an increased risk of multiple sclerosis.
• HLA-B*58:01 Allele: Associated with severe cutaneous adverse reactions to allopurinol (gout medication).
• HLA-A*31:01 Allele: Linked to carbamazepine hypersensitivity in European and Asian populations.
• HLA-B*51 Allele: Strongly associated with Behçet’s disease, a rare inflammatory disorder causing vasculitis.
• HLA-Cw*06:02 Allele: Associated with psoriasis vulgaris and psoriatic arthritis.
• Mismatched Loci Identification: Quantifies the exact number of HLA mismatches between a patient and a prospective donor (e.g., 1-antigen mismatch, 2-antigen mismatch).
• Homozygosity vs. Heterozygosity: Determines whether the patient has inherited identical (homozygous) or different (heterozygous) HLA alleles from their parents.
• High-Resolution Allele Typing: Provides precise, four-digit resolution (e.g., HLA-A*02:01) necessary for bone marrow donor registries.

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, we understand that HLA tissue typing is often a time-sensitive test, particularly for patients awaiting urgent organ transplants or preparing for chemotherapy and stem cell rescue. Because HLA typing involves complex molecular extraction, amplification, and high-resolution analysis, the processing time is longer than standard blood tests. Typically, results are compiled, verified by a consultant pathologist, and released within 5 to 7 working days.

Lahore PCR Lab provides a seamless and secure digital reporting system. Once the clinical report is finalized, patients receive an automated SMS notification on their registered mobile number. Reports can be accessed, viewed, and downloaded directly from the official Lahore PCR Lab online portal. Additionally, physical copies of the verified reports can be collected from the main laboratory facility or designated collection centers across Lahore, ensuring convenient access for both patients and their referring specialists.

HLA 1 & 2 Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
HLA-A Loci (Class I)	Normal expression of standard maternal and paternal HLA-A alleles.	Specific alleles associated with transplant mismatch or disease susceptibility.
HLA-B Loci (Class I)	Normal expression of standard maternal and paternal HLA-B alleles.	Presence of high-risk alleles such as HLA-B*27, HLA-B*5701, or HLA-B*1502.
HLA-C Loci (Class I)	Normal expression of standard maternal and paternal HLA-C alleles.	Presence of HLA-Cw*06:02 (psoriasis risk) or alleles incompatible with a donor.
HLA-DRB1 Loci (Class II)	Normal expression of standard maternal and paternal HLA-DRB1 alleles.	Presence of HLA-DR4 (rheumatoid arthritis risk) or donor-recipient mismatch.
HLA-DQB1 Loci (Class II)	Normal expression of standard maternal and paternal HLA-DQB1 alleles.	Presence of HLA-DQ2.5 or HLA-DQ8 (celiac disease susceptibility).
Transplant Compatibility Index	High compatibility (e.g., 8/8 or 10/10 match) between patient and donor.	Low compatibility (multiple mismatches), increasing risk of rejection or GVHD.
Drug Hypersensitivity Markers	Negative for HLA-B*5701, HLA-B*1502, and HLA-B*58:01.	Positive for specific alleles, indicating high risk of severe drug reactions.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for HLA 1 & 2 Tissue Typing?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified molecular biologists, geneticists, and consultant pathologists specializing in histocompatibility and immunogenetics.
• Patient-Focused Care: We prioritize patient comfort, safety, and clear communication throughout the sample collection and reporting process.
• Quality Diagnostic Services: Lahore PCR Lab adheres to stringent national and international quality control standards to ensure the highest diagnostic accuracy.
• Professional Reporting: Reports are detailed, comprehensive, and structured to provide clear, actionable genetic data for clinical specialists.
• Modern Diagnostic Approach: We utilize advanced PCR-based technologies and state-of-the-art molecular platforms for high-resolution allele identification.
• Comfortable Environment: Our diagnostic center in Lahore offers a clean, hygienic, and welcoming environment for all patients.
• Convenient Location: Easily accessible main facility and collection points across Lahore make it simple for patients to access our services.
• Commitment to Accurate Diagnosis: We are dedicated to delivering precise, reproducible results that physicians can trust for critical medical decisions.